AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

AC Immune S.A.NASDAQ: ACIU

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of CHF 1.12M rose 13.0% year over year, ahead of the -86.9% change in trailing-twelve-month gross profit. Sequentially, it rose 231.1% from the prior quarter. Over 3 fiscal years it compounded at -3.2% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, down 29.1 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +13.0% holds above the trailing-twelve-month pace of -86.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 1.12M+231.1% QoQ
Last fiscal yearDec 2025
CHF 3.57M+110.1% YoY
LTMMar 2026
CHF 3.7M-86.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.0%——
1 year+110.1%——
3-year CAGR-3.2%——
5-year CAGR——
10-year CAGR——

Gross Profit history

CHF · from the income statement

Latest · FY2025
3.57M CHF
Year-over-year change
+110.1%

Gross Profit vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -86.9% is the 5th highest of 6, against a peer median of +43.8%.
  • Gross profit amounts to 100.0% of revenue for ACIU, versus a peer median of 81.9%.
ACIU Competitors
Gross Profit for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$112.77M USD+52.6%-20.7%52.5%
CLLSCellectis S.A.LTM Mar 2026$55.76M USD+43.8%+80.8%81.9%
ACIUAC Immune S.A.LTM Mar 2026CHF 3.7M CHF-86.9%-3.2%100.0%
SLNSilence Therapeutics plcLTM Mar 2026$612.12K USD—-62.8%66.4%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$0 USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$66.6K USD———
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$79K USD———
ANROAlto Neuroscience, Inc.LTM Mar 2026-$284K USD-67.1%——
MREOMereo BioPharma Group plcLTM Mar 2026-$528.63K USD+51.3%+12.5%105.7%
ANNXAnnexon, Inc.LTM Mar 2026-$1.9M USD———
LYELLyell Immunopharma, Inc.LTM Mar 2026-$2.3M USD-3640.0%—7422.6%
Peer median (excluding ACIU) —+43.8%-4.1%81.9%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.94M14.8M27.31M3.57M
Cost of Revenue0054.61M62.57M0
Gross Profit03.94M(39.81M)(35.26M)3.57M
Gross Margin—100.0%-268.9%-129.1%100.0%
Research & Development62.28M60.34M54.61M62.57M56.44M
Selling, General & Admin10.88M9.58M10.58M11.43M11.65M
Operating Expenses79.01M74.78M13.82M17.12M72.44M
Depreciation & Amortization2.41M2.36M2.22M2.16M2.5M
EBITDA(70.01M)(68.03M)(51.83M)(48.62M)(67.75M)
EBITDA Margin—-1728.7%-350.2%-178.0%-1896.2%
Operating Income(79.01M)(70.85M)(53.62M)(52.38M)(68.86M)
Operating Margin—-1800.4%-362.3%-191.8%-1927.3%
Interest Income6.49M69K1.04M3.2M1.87M
Interest Expense581K355K176K133K191K
Other Income / Expenses6.02M107K(599K)1.47M(1.58M)
Income Before Tax(72.99M)(70.74M)(54.22M)(50.91M)(70.45M)
Pre-Tax Margin—-1797.7%-366.3%-186.4%-1971.6%
Income Tax Expense3K13K10K3K0
Net Income(73M)(70.75M)(54.23M)(50.92M)(70.45M)
Net Margin—-1798.0%-366.4%-186.4%-1971.6%
EPS (Basic)(0.97)(0.85)(0.64)(0.51)(0.70)
EPS (Diluted)(0.97)(0.85)(0.64)(0.51)(0.70)
Weighted Avg Shares74.95M83.55M84.69M99.69M100.75M
Weighted Avg Shares (Diluted)74.95M83.55M84.69M99.69M100.75M

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.